Buoyed by Bumper Profits, WuXi Biologics Seeks to Bolster Global Supply Chain
Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would…
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Shiyue Daotian reaps profits on bumper move to corn
9676.HK
-
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
Youdao looks to parent, global markets to revive stalling growth
DAO.US
